DXB 3.16% 9.2¢ dimerix limited

Wanted to go with "Thunderbirds are GO", but though it was best...

  1. 132 Posts.
    lightbulb Created with Sketch. 6
    Wanted to go with "Thunderbirds are GO", but though it was best to stick with Dimerix.

    With DXB being oversubscribed by $2 million (after allocations were scaled back), I think we are all very pleased to know that DXB is now free of any financial burden and can confidently proceed into Phase 2B with their lead compound DMX-200. After the funds were confirmed last week a few here on HC speculated at how valuable DXB will become? Only time will tell whether DXB will be worth more or less than VLA's $500 million take over offer.

    For now I'm curious to get opinions on how others think DMX-200 will be developed/marketed?

    I'm no doctor so please correct me if I'm inaccurate, but from what I understand DXB is looking to develop DMX-200 on 2 fronts:

    1) Phase 2B trial of DMX-200 for rare kidney disease FSGS which will start before end March 2018, and

    2) Phase 2B trial of DMX-200 for Diabetic Nephropathy (think I read somewhere that this is now 2019??).

    So what do you think the plan is?

    As initial/final results come in for FSGS, does DXB do a deal using Diabetic Nephropathy as an upside carrot (as the results from Phase 2A where positive, albeit from a small test group), or can they do a deal for FSGS only and continue separately with Diabetic Nephropathy?


watchlist Created with Sketch. Add DXB (ASX) to my watchlist
(20min delay)
Mkt cap ! $14.60M
Open High Low Value Volume
9.2¢ 9.2¢ 9.2¢ $4.768K 51.82K

Buyers (Bids)

No. Vol. Price($)
2 206000 9.0¢

Sellers (Offers)

Price($) Vol. No.
9.2¢ 3174 1
View Market Depth
Last update - 15.58pm 23/08/2019 (20 minute delay) ?
-0.003 ( 3.16 %)
Open High Low Volume
9.2¢ 9.2¢ 9.2¢ 3404
Last updated 15.58pm 23/08/2019 (live) ?
DXB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.